Stock listing
GANX Stock Price, News, Filings & Events — Gain Therapeutics, Inc.
Selected listing: GANX · BOATS · USD · US
This page tracks Gain Therapeutics, Inc.'s GANX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following GANX:BOATS. GANX:BOATS is the stock-level entry point for investors researching Gain Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Gain Therapeutics, Inc. (ticker: GANX) is a public company based in the United States, with a market capitalization of approximately $72.9 million. The company focuses on developing innovative therapies for various diseases. Gain Therapeutics is committed to advancing its research and development efforts to bring new treatment options to market.

- Ticker
- GANX:BOATS
- Asset type
- Stock
- Market cap
- $92.5M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Gain Therapeutics, Inc. GANX:BOATS stock context
This page tracks Gain Therapeutics, Inc.'s GANX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following GANX:BOATS. GANX:BOATS is the stock-level entry point for investors researching Gain Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Gain Therapeutics, Inc. (ticker: GANX) is a public company based in the United States, with a market capitalization of approximately $72.9 million. The company focuses on developing innovative therapies for various diseases. Gain Therapeutics is committed to advancing its research and development efforts to bring new treatment options to market.
Latest news from Gain Therapeutics, Inc.
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
August 25, 2026
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
August 11, 2026
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
July 16, 2026
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 10, 2026
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
May 26, 2026
Research Gain Therapeutics, Inc.
Gain Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for GANX:BOATS.
Gain Therapeutics, Inc. company profile
View the public company page for Gain Therapeutics, Inc. on 6ix.
Gain Therapeutics, Inc. news
Read company news and market updates connected to Gain Therapeutics, Inc..
Gain Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Gain Therapeutics, Inc..